S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
NASDAQ:PLRX

Pliant Therapeutics - PLRX Stock Forecast, Price & News

$34.00
-0.45 (-1.31%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$33.55
$35.51
50-Day Range
$17.00
$36.26
52-Week Range
$3.96
$36.64
Volume
541,047 shs
Average Volume
1.50 million shs
Market Capitalization
$1.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.11

Pliant Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
38.6% Upside
$47.11 Price Target
Short Interest
Healthy
6.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.02mentions of Pliant Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$7.44 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.89) to ($3.04) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

85th out of 1,030 stocks

Pharmaceutical Preparations Industry

30th out of 502 stocks

PLRX stock logo

About Pliant Therapeutics (NASDAQ:PLRX) Stock

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLRX Stock News Headlines

Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.
Pliant Gets FDA Clearance INDA For PLN-101095 To Treat Solid Tumors
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Techne (TECH) Q2 Earnings and Revenues Miss Estimates
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
Pliant Therapeutics (NASDAQ:PLRX) PT Raised to $52.00
Needham Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
See More Headlines
Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLRX Company Calendar

Last Earnings
11/08/2022
Today
2/02/2023
Next Earnings (Estimated)
2/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PLRX
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.11
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+38.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-97,260,000.00
Net Margins
-1,160.53%
Pretax Margin
-1,160.53%

Debt

Sales & Book Value

Annual Sales
$9.72 million
Book Value
$5.52 per share

Miscellaneous

Free Float
45,541,000
Market Cap
$1.66 billion
Optionable
Not Optionable
Beta
1.40

Key Executives

  • Dr. Bernard Coulie M.B.A. (Age 56)
    M.D., MBA, Ph.D., Pres, CEO & Director
    Comp: $889.01k
  • Dr. Keith Lamont Cummings M.B.A. (Age 45)
    M.D., Chief Financial Officer
    Comp: $606.12k
  • Mr. Mike Ouimette (Age 49)
    Gen. Counsel & Corp. Sec.
    Comp: $537.99k
  • Mr. Johannes P. Hull (Age 47)
    Chief Bus. Officer
    Comp: $582.49k
  • Dr. Éric Lefebvre M.D. (Age 58)
    Chief Medical Officer
    Comp: $713.81k
  • Dr. Rik Derynck
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Dean Sheppard M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Bill DeGrado Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Hal Chapman M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Craig D. Muir
    Interim Chief Technology Officer













PLRX Stock - Frequently Asked Questions

Should I buy or sell Pliant Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PLRX shares.
View PLRX analyst ratings
or view top-rated stocks.

What is Pliant Therapeutics' stock price forecast for 2023?

9 Wall Street research analysts have issued 12 month target prices for Pliant Therapeutics' shares. Their PLRX share price forecasts range from $33.00 to $55.00. On average, they expect the company's stock price to reach $47.11 in the next twelve months. This suggests a possible upside of 37.0% from the stock's current price.
View analysts price targets for PLRX
or view top-rated stocks among Wall Street analysts.

How have PLRX shares performed in 2023?

Pliant Therapeutics' stock was trading at $19.33 at the beginning of 2023. Since then, PLRX stock has increased by 77.9% and is now trading at $34.38.
View the best growth stocks for 2023 here
.

When is Pliant Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our PLRX earnings forecast
.

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted its quarterly earnings data on Tuesday, November, 8th. The company reported ($0.65) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.09. The company earned $1.48 million during the quarter, compared to analysts' expectations of $2.26 million. Pliant Therapeutics had a negative trailing twelve-month return on equity of 52.61% and a negative net margin of 1,160.53%.

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), Ampio Pharmaceuticals (AMPE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

When did Pliant Therapeutics IPO?

(PLRX) raised $90 million in an IPO on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.

What is Pliant Therapeutics' stock symbol?

Pliant Therapeutics trades on the NASDAQ under the ticker symbol "PLRX."

Who are Pliant Therapeutics' major shareholders?

Pliant Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include New York State Common Retirement Fund (0.04%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette.
View institutional ownership trends
.

How do I buy shares of Pliant Therapeutics?

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pliant Therapeutics' stock price today?

One share of PLRX stock can currently be purchased for approximately $34.38.

How much money does Pliant Therapeutics make?

Pliant Therapeutics (NASDAQ:PLRX) has a market capitalization of $1.68 billion and generates $9.72 million in revenue each year. The company earns $-97,260,000.00 in net income (profit) each year or ($2.93) on an earnings per share basis.

How can I contact Pliant Therapeutics?

Pliant Therapeutics' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is pliantrx.com. The company can be reached via phone at 650-481-6770 or via email at ir@pliantrx.com.

This page (NASDAQ:PLRX) was last updated on 2/3/2023 by MarketBeat.com Staff